The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The current approaches to treating DLBCL in the frontline and relapsed settings
Grzegorz Nowakowski, MD, Mayo Clinic, Rochester, MN, speaks on the current frontline treatment options for patients with diffuse large B-cell lymphoma (DLBCL), including R-CHOP chemotherapy. Dr Nowakowski introduces CAR T-cell therapy as a promising option for eligible relapsed patients and expresses his enthusiasm for other novel agents that could revolutionize second and third-line treatment. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: MorphoSys, Celgene/Bristol Myers Squibb, Roche, Genentech, Kyte Pharma, Ryvu Therapeutics, Selvita, Curis, Karyopharm Therapeutics, Bantham Pharmaceutical, Daiichi Sankyo, Zai Labolatory, Incyte, Kymera Therapeutics, TG Therapeutics, Blueprint Medicines
